

ATTACHMENT C
DDP Remaining Liability

Pharmaceutical Company	DDP Liability Remaining	% Remaining of Total Program Liability
AHP/American Cyanamid (Wyeth)	\$ 5,238,396	32.63%
SmithKline Beecham (Glaxo-Smithkline)	\$ 2,817,690	25.14%
Novartis	\$ 2,398,672	32.28%
Upjohn (Pharmacia)*	\$ 2,361,413	23.62%
Searle (Pharmacia)*	\$ 1,197,453	49.06%
Abbott	\$ 954,098	18.51%
Merck*	\$ 629,998	3.22%
Glaxo-Wellcome (Glaxo-SmithKline)	\$ 432,315	2.23%
Boehringer-Ingelheim*	\$ 416,983	16.55%
Rhone-Poulenc Rorer (Aventis)	\$ 327,488	11.03%
Zeneca*	\$ 132,019	2.27%
Knoll (Abbott)*	\$ 66,433	4.86%
Carter Wallace (Church & Dwight)	\$ 169	0.02%
Schering-Plough Schering*	\$ 135	0.00%
Pfizer*	\$ 67	0.00%
Roche	\$ 59	0.00%
Warner Lambert (Pfizer)	\$ 13	0.00%
Dupont (Bristol Myers Squibb)	\$ 13	0.00%
Hoechst-Marion Roussel (Aventis)	\$ 6	0.00%
Bristol-Myers Squibb	\$ 6	0.00%
Eli Lilly & Co.*	\$ 1	0.00%
Janssen (Johnson & Johnson)	\$ -	0.00%
Ortho-McNeil (Johnson & Johnson)	\$ -	0.00%
	\$ 16,973,427	
*See Attachment B footnotes regarding confirmation of data.		